A086890 Stock Overview
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ISU Abxis Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,060.00 |
| 52 Week High | ₩8,410.00 |
| 52 Week Low | ₩5,250.00 |
| Beta | 0.75 |
| 1 Month Change | 3.82% |
| 3 Month Change | 24.96% |
| 1 Year Change | 12.60% |
| 3 Year Change | -68.27% |
| 5 Year Change | -9.25% |
| Change since IPO | -23.26% |
Recent News & Updates
Shareholder Returns
| A086890 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.4% | -4.0% | -3.3% |
| 1Y | 12.6% | 0.7% | 1.2% |
Return vs Industry: A086890 exceeded the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A086890 exceeded the KR Market which returned 1.2% over the past year.
Price Volatility
| A086890 volatility | |
|---|---|
| A086890 Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A086890 has not had significant price volatility in the past 3 months.
Volatility Over Time: A086890's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Yeob Hwang | www.abxis.com |
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.
ISU Abxis Co., Ltd. Fundamentals Summary
| A086890 fundamental statistics | |
|---|---|
| Market cap | ₩245.48b |
| Earnings (TTM) | ₩3.61b |
| Revenue (TTM) | ₩54.31b |
68.0x
P/E Ratio4.5x
P/S RatioIs A086890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086890 income statement (TTM) | |
|---|---|
| Revenue | ₩54.31b |
| Cost of Revenue | ₩19.20b |
| Gross Profit | ₩35.11b |
| Other Expenses | ₩31.50b |
| Earnings | ₩3.61b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 103.84 |
| Gross Margin | 64.65% |
| Net Profit Margin | 6.65% |
| Debt/Equity Ratio | 83.5% |
How did A086890 perform over the long term?
See historical performance and comparison